Esophagus, Esophagus GE Junction, Stomach
|
|
- Eric Mills
- 6 years ago
- Views:
Transcription
1 Esophagus, Esophagus GE Junction, Stomach Education and Training Team Collaborative Stage Data Collection System Version v02.03 Learning Objectives Understand rationale behind changes and updates Understand use of codes and reporting Determine proper code use for accurate reporting Understand finding specific documentation SSFs Coding rules 2 Outline Overview of the following schemas: Esophagus Esophagus GE Junction Stomach Review Collaborative Stage data items for schemas Describe changes to schemas in CSv2 3 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 1
2 Esophagus ICD-O-3 Topography Based on Landmarks Cervical esophagus (C15.0) Thoracic esophagus (C15.1) Upper Thoracic Mid Thoracic Abdominal esophagus (C15.2) Lower Thoracic Based on Measurement Upper 1/3 esophagus (C15.3) Proximal third of esophagus Middle 1/3 esophagus (C15.4) Mid third of esophagus Lower 1/3 esophagus (C15.5) Distal esophagus 5 Esophagus & Esophagus GE Junction: Histologies Adenocarcinoma Usually forms in the lower third of the esophagus, near the stomach. Squamous Cell Carcinoma Typically found in the upper two thirds of the esophagus. Histologies Stage Table Assign all ICD-O-3 histology codes to either the Adenocarcinoma or Squamous staging tables 6 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 2
3 Esophagus: Adenocarcinoma/Squamous Cell Carcinoma Effective with AJCC TNM 7th Edition, there are separate stage groupings for squamous cell carcinoma and adenocarcinoma. Since squamous cell carcinoma typically has a poorer prognosis than adenocarcinoma, a tumor of mixed histopathologic type or a type that is not otherwise specified should be classified as squamous cell carcinoma. Applies to both Esophagus and EGJ schema AJCC TNM 7 Stage Squamous AJCC TNM 7 Stage Adenocarcinoma 7 Esophagus: The Histologies Stage Table 8 9 Esophagus AJCC 7 th edition stage derived from: T(CS Extension) N(CS Lymph nodes) & Regional Nodes Positive M(CS Mets at Dx) Eval codes (for clinical/pathologic staging) Grade Histology (Adenocarcinoma vs Squamous Cell) SSF 1: Clinical assessment of regional lymph nodes For clinical cases SSF 2: Specific Location of tumor For Squamous cell carcinomas only CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 3
4 Esophagus: High Grade Dysplasia The terminology preferred by pathologists for carcinoma in situ of the esophagus is high grade dysplasia. This terminology is not reportable to most cancer registries. Therefore, it may be a future issue that early/very low stage esophageal cancer is under-reported as a result of registry reporting terminology. If high grade dysplasia of the esophagus is a reportable cancer, it should be coded as 00 in CS Extension. CS Manual Section I Part 2 Page 33 Version Esophagus: CS Extension OBSOLETE CODES 600 (v02.00): See codes (v02.03): See codes 615, 720, (v02.00): See codes (v02.00): See code (v02.00): See codes Esophagus: CS Extension-v02.03 Code 130: Stated as T1a Code 165: Stated as T1b Code 815: Stated as T4 [NOS] or invasion of adjacent structures, NOS 12 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 4
5 Esophagus: CS Extension Code 615: Initially in code 610 Tumor invades adjacent structures for cervical and intrathoracic esophagus (upper or middle) Maps to T4a Tumor invades Azygos vein moved to new code Code 720: Initially in code 610 Tumor invades adjacent structures for intrathoracic esophagus: Azygos vein Maps to T4b Code 725: Esophagus: CS Extension Code 728: Azygos vein (upper/middle esophagus) + Pericardium (middle esophagus) Code 740: Tumor invades adjacent structures + Pericardium (middle esophagus) Code 745: Tumor invades adjacent structures + Pleura (upper esophagus, diaphragm fixed (lower esophagus) 14 Esophagus: CS Lymph Nodes Code 255: any of (100, 200, 220) Cervical (upper) + Celiac (lower) lymph nodes + other named regional lymph nodes (code 100) or scalene/supraclavicular (cervical) and superior mediastinal (upper) 15 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 5
6 Esophagus: CS Lymph Nodes Code 260: OBSOLETE v02.03 Code 265: Code 260 minus the following: Common hepatic now Mets at Dx code 15 Splenic now Mets at Dx code 15 Codes 270, 275 and 280: Combination codes Note: Code 260 refers to Mets at Dx codes 15, 55 This should be code 15, 50 (the 55 is a typo) Fixed in v Esophagus: CS Lymph Nodes Code 300: OBSOLETE v02.03 Code 305: Code 300 minus the following: Common hepatic now Mets at Dx code 15 Splenic now Mets at Dx code 15 Codes 310, 320, 330: Combination codes 17 Esophagus: CS Lymph Nodes Code 560: Stated as pathologic N1 Code 600: OBSOLETE v02.03 Stated as clinical N2 (no lymph nodes removed) See code 500 (regional lymph nodes, NOS) Code 700: OBSOLETE v02.03 Stated as clinical N3a (no lymph nodes removed) See code 500 (regional lymph nodes, NOS) Only use pathologic stated as codes in CS Lymph nodes (560, 610, 710) 18 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 6
7 19 Esophagus: CS Lymph Nodes Pathologic N derived from CS Lymph Nodes (codes ) and Reg Nodes Pos CS Lymph node eval code 2, 3, 6, 8 N1: Metastasis in regional lymph nodes Regional nodes positive coded N2: Metastasis in regional lymph nodes N3: Metastasis in regional lymph nodes Code 500 when number of positive nodes available, but names of nodes not documented Code 800 when unknown if regional or distant ALWAYS defaults to a N1 Esophagus: CS Mets at Dx Codes 11 & 12: OBSOLETE v02.00 Defined as regional in AJCC 7 th edition, see CS Lymph node codes 250 and 265 Still mapped as mets at dx for AJCC 6 th edition Code 15: Common hepatic and splenic From CS Lymph nodes code Esophagus SSF 1: Clinical Assessment of Regional Lymph Nodes Code clinical stated as codes in SSF 1 100: Stated as N1 1-2 positive nodes, clinically 200: Stated as N2 3-6 regional nodes positive, clinically 300: Stated as N3 7 or more regional nodes positive, clinically 400: Clinically positive regional nodes positive No other information on clinical status of nodes 21 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 7
8 Esophagus SSF 1: Clinical Assessment of Regional Lymph Nodes Deriving Clinical N CS Lymph nodes 000, automatically derived CS Lymph nodes use extra table Lymph Nodes Clinical Evaluation AJCC 7 Table CS Lymph nodes CS Lymph nodes eval code 0, 1, 5, 9 N derived from combination of regional nodes positive and SSF 1 22 Esophagus SSF 2: Specific Location of Tumor Staging element for squamous cell tumors Collect for all histologies AJCC definition of location: Position of upper (proximal) edge of tumor in esophagus Location of tumor provides information about extension to adjacent structures Coding a upper thoracic esophagus tumor ICD-O-3: C15.1 (Thoracic esophagus) SSF #2: 020 (Stated as upper thoracic esophagus) 23 Esophagus SSF 3: Number of Regional Nodes with Extracapsular Tumor Tumor involvement of lymph node which spills beyond the wall of the node into surrounding fat Poor prognostic factor Information found in pathology report If extracapsular ext. noted to be negative, code 000 If no mention of extracapsular ext., code 990 If lymph node examination done and results not available, code 997 If no pathologic assessment of lymph nodes, code CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 8
9 Esophagus SSF 4: Distance to Proximal Edge of Tumor from Incisors Measures distance from incisors (teeth) to the uppermost (proximal) point of the tumor Codes : code to nearest centimeter Codes : range codes for when exact distance is not available Code 999: unknown 25 Esophagus SSF 5: Distance to Distal Edge of Tumor from Incisors Measures distance from incisors (teeth) to the lowermost(distal) point of the tumor Codes : code to nearest centimeter Codes : range codes for when exact distance is not available Code 999: unknown 26 Esophagogastric Junction CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version: 1.0 9
10 Esophagus & Esophagus GE Junction: Histologies Adenocarcinoma Usually forms in the lower third of the esophagus, near the stomach. Squamous Cell Carcinoma Typically found in the upper two thirds of the esophagus. Histologies Stage Table Assign all ICD-O-3 histology codes to either the Adenocarcinoma or Squamous staging tables 28 Esophagus GE Junction AJCC 7 th edition stage derived from: T(CS Extension) N(CS Lymph nodes) & Regional Nodes Positive M(CS Mets at Dx) Eval codes (for clinical/pathologic staging) Grade Histology (Adenocarcinoma vs Squamous Cell) SSF 1: Clinical assessment of regional lymph nodes For clinical cases SSF 25: Schema discriminator 29 Esophagus GE Junction: CS Extension OBSOLETE CODES 130 (v02.00): Polyps not relevant for schema 140 (v02.03): Polyps not relevant for schema 430 (v02.03): See code (v02.03): See codes 570, 605, (v02.03): See codes 570, (v02.03): See code (v02.03): See code (v02.03): See code CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
11 Code Esophagus GE Junction: CS Extension-v02.03 New Codes Explanation 125 Stated as T1a 480 Stated as T3 (previously coded 430) 570 Pericardium, Pleura, Diaphragm (previously coded 600) 580 Stated as T4a (previously coded 720) 605 Code 600 minus organs now listed in codes 570 (also includes transverse colon, including flexures) 615 Combination of codes 570 and Stated as T4b (previously coded 820) 810 Stated as T4 [NOS] (previously coded 720) 31 Esophagus GE Junction: CS Lymph Nodes Named regional lymph nodes: Code 100: Multiple named lymph nodes Code 400: Celiac lymph nodes Code 450: Paraesophageal/Periesophageal Regional lymph nodes, NOS Code 500: Regional lymph nodes, NOS Lymph nodes, NOS Code 800: Lymph nodes, NOS 32 Esophagus GE Junction: CS Lymph Nodes Code 610: Stated as pathologic N1 Code 650: OBSOLETE v02.03 Stated as clinical N2 (no lymph nodes removed) See code 500 (regional lymph nodes, NOS) Code 700: OBSOLETE v02.03 Stated as clinical N3a (no lymph nodes removed) See code 500 (regional lymph nodes, NOS) Only use pathologic stated as codes in CS Lymph nodes (610, 660, 720) 33 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
12 34 Esophagus: CS Lymph Nodes Pathologic N derived from CS Lymph Nodes (codes ) and Reg Nodes Pos CS Lymph node eval code 2, 3, 6, 8 N1: Metastasis in regional lymph nodes Regional nodes positive coded N2: Metastasis in regional lymph nodes N3: Metastasis in regional lymph nodes Code 500 when number of positive nodes available, but names of nodes not documented Code 800 when unknown if regional or distant ALWAYS defaults to a N1 Esophagus GE Junction: CS Mets at Dx Code 10: Distant lymph nodes Code 40: Distant mets (except distant LN s) Code 50: Distant mets & distant lymph nodes Code 60: Distant mets, NOS Stated as M1 with no other info on Mets Code 99: Unknown if mets 35 Esophagus GE Junction: SSF 25 Schema Discriminator Primary site codes C16.0, C16.1, C16.2 For primary site codes C16.3-C16.9, code 981 for the stomach schema Cases coded to C16.0-automatically go to EGJ schema (use code 010) 36 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
13 Stomach Stomach AJCC 7 th edition stage derived from: T(CS Extension) N(CS Lymph nodes) & Regional Nodes Positive M(CS Mets at Dx) Eval codes (for clinical/pathologic staging) SSF 1: Clinical assessment of regional lymph nodes For clinical cases SSF 25: Schema discriminator Needed for primary sites C16.0, C16.1 and C Stomach: Histologies Adenocarcinoma, NOS (42.9%) Signet ring cell carcinoma (15.6%) Adenocarcinoma, Intestinal type (7.2%) Lymphomas (10.1%) NHL, large B-cell diffuse Marginal zone B-cell lymphoma, NOS Others 39 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
14 Stomach: CS Extension New Codes for Version 2 125: Stated as T1a 170: Stated as T1b 180: Stated as T1 [NOS] (previously340) 390: Stated as T2 480: Stated as T3 555: Stated as T4a (previously 500) 805: Stated as T4b (previously 690) 810: Stated as T4 [NOS] (previously 490) 40 Stomach: CS Extension T1a: Invasion of lamina propria or muscularis mucosae T1b: invasion of the submucosa T2: Invasion of the muscularis propria T3: Invasion of the subserosal connective tissue (no invasion of serosa or adjacent structures) T4a: Penetrates the serosa T4b: Invades adjacent structures 41 Stomach: CS Extension Intraluminal extension (T1a and T1b) Occurring within, or introduced into the lumen AJCC 7 th edition: Intramural (intraluminal) extension is classified by depth of greatest invasion) See Note 1, Ext 3 new codes have intraluminal extension as part of their description Code 122 (T1a) Code 165 (T1b) Code 360 (T2) 42 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
15 Stomach: CS Extension Code 500 (CSv1), OBSOLETED and divided Code 505: Invasion of/through serosa If invasion of serosa AND extension to adjacent structures, see codes 610, 650 and 700 Code 551: Invasion of serosa and Extension to adjacent connective tissue Code 555: Stated as T4a (previously in 500) 43 Stomach: CS Extension Adjacent structures of the Stomach (Ext code 610, T4b) Spleen Transverse Colon Liver Diaphragm Pancreas Abdominal wall Adrenal gland Kidney Small Intestine Retroperitoneum 44 7 th edition AJCC manual, p. 120 Stomach: CS Extension OBSOLETE Code 600 (extension to adjacent structures) now divided into: Code 610: All structures in code 600 MINUS Aorta and Celiac Axis Maps to Summary Stage Regional Code 650: Aorta and Celiac Axis Maps to Summary Stage Distant 45 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
16 Stomach: CS Lymph Nodes Left gastric Pancreaticosplenic Pancreatoduodenal Perigastric, NOS Peripancratic Right gastric Superior mesenteric Celiac Hepatic Hepatoduodenal (for lesser curvature only) 46 Stomach: CS Lymph Nodes Code 100: OBSOLETE Includes see also code 050 No code 050. Will be removed in future version Code 110: Same as code 100 MINUS Superior mesenteric Superior mesenteric coded in Mets at Dx code Stomach: CS Lymph Nodes Code 600: OBSOLETE v02.03 Stated as N1 See codes 500, 610, SST 1 code 100 Code 650: OBSOLETE v02.03 Stated as N2 See codes 500, 660, SSF 1 code 200 Code 700: OBSOLETE Stated as N3 See codes 500, 750, SSF 1 code CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
17 Stomach: CS Lymph Nodes Pathologic N derived from CS Lymph Nodes (codes ) and Reg Nodes Pos CS Lymph node eval code 2, 3, 6, 8 N1: Metastasis in regional lymph nodes N2: Metastasis in regional lymph nodes N3a: Metastasis in regional lymph nodes N3b: Metastasis in 16 or more regional lymph nodes Code 500 when number of positive nodes available, but names of nodes not documented Code 800 when unknown if regional or distant ALWAYS defaults to a N1 49 Stomach: CS Mets at Dx Common Metastatic Sites Liver Peritoneal surfaces Malignant peritoneal cytology is classified as metastatic disease Distant lymph nodes Retropancreatic Para-aortic Portal Retroperitoneal Mesenteric 50 Stomach: CS Mets at Dx Code 10: Distant lymph nodes Includes Superior mesenteric from old LN code 100 Code 40: Distant mets, INCLUDING positive peritoneal cytology Code 50: Codes Code 60: Distant mets, NOS; Stated as M1 51 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
18 CS SSF1: Stomach-Clinical Assessment of Regional Lymph Nodes Documents clinical assessment of regional lymph nodes prior to treatment When clinically positive nodes stated: 100: 1-2 regional lymph nodes (N1) 200: 3-6 regional lymph nodes (N2) 300: 7 or more regional lymph nodes (N3) 310: 7-15 regional lymph nodes (N3a) 320: 16 or more regional lymph nodes (N3b) 52 CS SSF2: Stomach Specific Location of Tumor Clinically significant prognostic factor Identifies specific location of the tumor within the stomach Provides more specificity of tumor location than ICD-O-3 Tumor identified in anterior wall of antrum ICD-O-3: C16:3-Gastric antrum SSF #2: 090- Antrum Anterior wall 53 SSF13: Stomach Carcinoembryonic Antigen (CEA) Same coding instructions as given for coding CEA values for Colon Code the interpretation of highest lab value of CEA prior to treatment If no documentation of test in record, code 999 Do NOT assume it was not done Code 998 may be done if you know the test was not done on the patient or your facility routinely does not do CEA s on Stomach cancer patients 54 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
19 CS SSF14: Stomach Carcinoembryonic Antigen (CEA) Lab Value Record in nanograms/milliliter highest CEA lab value prior to treatment Needs to be in agreement with SSF #13 If test not done coded for SSF #13, test not done needs to be coded for SSF #14 If coded unknown in SSF #13, unknown needs to be coded in SSF #14 55 CS SSF15: Stomach CA 19-9 Lab Value Record in units/milliliter the highest CA 19-9 lab value prior to treatment If no documentation of test in record, code 999 Do NOT assume it was not done Code 998 may be done if you know the test was not done on the patient or your facility routinely does not do CEA s on Stomach cancer patients Not required by any standard setters May use code CS SSF25: Stomach Involvement of Cardia & Distance from EGJ Fundus (C16.1) and body (C16.2) of stomach can be assigned to either EsophagusGEJunction or Stomach CSv2 schema SSF25 is schema discriminator field needed for CS algorithm to determine which schema to select when site is C16.1 or C CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
20 CAnswer Forum Submit questions to CS Forum Located within the CAnswer Forum Provides information for all Allows tracking for educational purposes Includes archives of Inquiry & Response System 58 American Joint Committee on Cancer Contact Information AJCC Web Site: Karen A. Pollitt Manager phone: Donna M. Gress, RHIT, CTR Technical Specialist phone: American Joint Committee on Cancer Contact Information Marty Madera Education Administrator phone: Judy Janes AJCC Coordinator phone: General Inquiries can be directed to or 60 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
21 Questions 61 Myeloma Plasma Cell Disorders (Schema Name: MyelomaPlasmaCellDisorder) V Learning Objectives Understand rationale behind changes and updates Understand use of codes and reporting Determine proper code use for accurate reporting Understand finding specific documentation SSFs Coding rules 63 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
22 Outline Overview of the schema Review Collaborative Stage data items for schema Describe changes to schema in CSv2 64 Myeloma Plasma Cell Disorders Schema new to v0203 Effective for cases diagnosed 1/1/2011+ and/or in v02.03 and after Schema developed based on 2010 Hematopoietic Coding Manual and Database For cases collected prior to CSv02.03 Automatically converted to new schema 65 Myeloma Plasma Cell Disorders Applicable for histologies: 9731 Plasmacytoma, NOS (except C441, C690, C695- C696) 9732 Multiple myeloma (except C441, C690, C695- C696) 9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696) 66 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
23 CS Data Items Not Applicable CS Tumor Size Code 988 CS Tumor Size/Ext Eval Code 9 CS Lymph Nodes Code 987 Only for histology's 9731 and 9732 CS Lymph Nodes Eval Code 9 CS Mets at Dx Code 98 CS Mets Eval Code 9 67 CS Extension All cases diagnosed prior to January 1, 2011 and originally coded prior to v0203, are coded to the following codes: Code 100 Localized disease (9731, 9734) Code 800 Systemic disease (9731, 9732, 9734) Code 999 Unknown (9731, 9734) Code 999 is valid in v0203 All extension codes are being retained 68 CS Extension 110: Single plasmacytoma without or unknown soft tissue extension (9731) Primary site is bone 200: Single plasmacytoma lesion WITH soft tissue extension (9731) Primary site is bone 300 Single plasmacytoma lesion occurring in tissue other than bone (9734) Primary site is not bone 69 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
24 CS Extension 400 Multiple osseous or multiple extraosseous plasmactyoma lesions (9731, 9734) For histology 9731, primary site is bone For histology 9734, primary site is NOT bone 500 Plasmacytoma, NOS (9731) Primary site defaults to bone Not stated if single or multiple lesions Not stated if osseous or extraosseous 70 CS Extension 810 Plasma cell myeloma (9732) Stated as multiple myeloma Stated as plasma cell myeloma Stated as myelomatosis 820 Myeloma, NOS (9732) Stated as myeloma with no other description 999 Unknown For codes 9731 and 9734 only Code 999 not to be used for histology CS Lymph nodes Applicable for histology code 9734 only Extraosseous plasmacytomas Occur in numerous sites, including respiratory tract (most common), GI tract, bladder, CNS, breast thyroid, testis and parotid gland These lesions may metastasize to regional lymph nodes 72 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
25 CS Lymph nodes Code 000: No evidence of regional lymph node involvement (code 9734) Code 100: Evidence of regional lymph node involvement (code 9734) Code 987: Use for histologies 9731 and 9732 Code 999: Unknown regional lymph node involvement; no documentation in record (code 9734) 73 # Positive, # Examined, LN Eval NOTE: In v0203, these fields are automatically not applicable These tables need to be replaced with the table that allows for recording the actual number of nodes examined and/or positive PLUS how the lymph node code was determined (for histology code 9734) This error will be fixed in the next revision of CSv2 For now, only code 99 will be acceptable for regional nodes positive and examined and code 9 for Lymph node eval 74 New Data Items Data Item Code Explanation Grade Path Value Blank Not applicable Grade Path System Blank Not applicable Lymph vascular invasion (LVI) 8 Not applicable Mets at Dx-Bone 8 Not applicable Mets at Dx-Lung 8 Not applicable Mets at Dx-Brain 8 Not applicable Mets at Dx-Liver 8 Not applicable 75 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
26 SSF1: JAK2 (OBSOLETE) This SSF is OBSOLETE for histologies 9731, 9732 and 9734 All old data retained Only allowable code is 988 for cases: Entered after v0203 update Cases diagnosed 1/1/2011 and after 76 SSF2: Durie-Salmon Staging System Specific to multiple myeloma (9732) only Stage is based on: Patient s hemoglobin level Serum calcium Paraprotein levels Urinary light chain excretions Number of lytic bone lesions identified on skeletal survey Stages are: IA, IB, IIA, IIB, IIIA, IIIB A or B designation based on the serum creatinine level 77 SSF2: Durie-Salmon Staging System Stage must be documented in record If stage documented but not stated as Durie Salmon, can assume it is and code the appropriate stage Do not calculate stage based on critiera (listed on previous slide) 78 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
27 SSF2: Durie-Salmon Staging System Code 010: Stage IA Code 020: Stage IB Code 030: Stage INOS Code 040: Stage IIA Code 050: Stage IIB Code 060: Stage IINOS 79 SSF2: Durie-Salmon Staging System Code 070: Stage IIIA Code 080: Stage IIIB Code 090: Stage IIINOS Code 987: Use for codes 9731 and 9734 Code 988: Can only be used for cases abstracted prior to v0203 or 1/1/2011 OR your standard setter does not require this SSF Code 999: Unknown, not documented in patient record 80 SSF3: Multiple Myeloma Terminology Specific to multiple myeloma (9732) only Variety of descriptive terms used to refer to early phases of myeloma These are reportable based on the 2010 Hematopoietic and Lymphoid Neoplasms coding rules This field captures the specific terminology used to describe the myeloma at TIME OF DIAGNOSIS 81 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
28 SSF3: Multiple Myeloma Terminology Code 000: Multiple myeloma/plasma cell myeloma with no other modifiers Code 010: Asymptomatic myeloma Code 020: Early myeloma, evolving myeloma Code 030: Inactive myeloma, idolent myeloma, smoldering myeloma 82 SSF3: Multiple Myeloma Terminology Code 080: Other terminology used to describe myeloma Code 100: Combination of terms in code Code 987: Use for codes 9731 and 9734 Code 988: Can only be used for cases abstracted prior to v0203 or 1/1/2011 OR your standard setter does not require this SSF Code 999: Unknown, not documented in patient record 83 Conclusion Histology codes 9731, 9732 and 9734 are now in the Myeloma Plasma Cell Disorder schema. Schema is applicable for all cases coded under v0203 or date of diagnosis 1/1/2011 and after Lymph nodes are to be coded for histology code 9734 SSF #1 is OBSOLETE and coded 988 for all cases coded in v0203 or date of diagnosis 1/1/2011 and after New SSF s 2 and 3 are for histology code 9732 only 84 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
29 Other Resources The 2010 Hematopoietic and Lymphoid Neoplasm rules are available on the SEER website at: Use these rules to help determine reportability, grade, primary site and histology ONLY Do not use these rules to apply stage 85 CAnswer Forum Submit questions to CS Forum Located within the CAnswer Forum Provides information for all Allows tracking for educational purposes Includes archives of Inquiry & Response System 86 American Joint Committee on Cancer Contact Information AJCC Web Site: Karen A. Pollitt Manager phone: Donna M. Gress, RHIT, CTR Technical Specialist phone: CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
30 American Joint Committee on Cancer Contact Information Marty Madera Education Administrator phone: Judy Janes AJCC Coordinator phone: General Inquiries can be directed to or 88 Questions 89 CSv2 Esophagus, EGJ, Stomach August 2011 Lecture Version:
Quiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
More informationCS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1.
CS Evaluation Fields Education and Training Team Collaborative Stage Data Collection System Version 02.03.02 (Effective date: 1/1/2011) Outline of Presentation Purpose AJCC TNM Classification Eval data
More informationVersion 2 Overview and Update CSv0202 to CSv0203
Version 2 Overview and Update CSv0202 to CSv0203 CS version 2 Education and Training Team What We ll Cover Rules changes and revisions CSv0202 to CSv0203 Sites with Major Changes Esophagus and Stomach
More informationGastric Cancer Histopathology Reporting Proforma
Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationGastric Cancer Staging AJCC eighth edition. Duncan McLeod Westmead Hospital, NSW
Gastric Cancer Staging AJCC eighth edition Duncan McLeod Westmead Hospital, NSW Summary of changes New clinical stage prognostic groups, ctnm Postneoadjuvant therapy pathologic stage groupings, yptnm -
More informationKyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System
Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data
More informationCOLLECTING CANCER DATA: STOMACH AND ESOPHAGUS
COLLECTING CANCER DATA: STOMACH AND ESOPHAGUS 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More information2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Grade PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgements Donna Hansen, CCR Jennifer Ruhl, NCI SEER Introduction 3 Histologic Type vs. Grade Credit: Dr. Kay Washington
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationEsophagus Stomach 4/2/15
Collecting Cancer Data: Esophagus & Stomach 2014-2015 NAACCR Webinar Series April 2, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
More informationCollaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ]
Collaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ] CS Tumor Size 000 No mass/tumor found 001-988 001-988 millimeters (code exact size in millimeters) 989 989 millimeters or larger 990 Microscopic
More informationTumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma
Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given
More informationSEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING
SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary
More informationAbstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:
Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 A 74 year old male with a history of GERD presents complaining of dysphagia. An esophagogastroduodenoscopy
More informationGreater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy
Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy Authors: Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments 1.1 Cancer reporting: Biopsies
More informationEsophageal Cancer Staging Essentials: The New TNM Staging System (7th edition) and Clinicoradiologic Implications
Esophageal Cancer Staging Essentials: The New TNM Staging System (7th edition) and Clinicoradiologic Implications Poster No.: E-0060 Congress: ESTI 2012 Type: Scientific Exhibit Authors: K. Lee, T. J.
More informationInteractive Discussion of Part I CS Coding Instructions: Working the Cases
Interactive Discussion of Part I CS Coding Instructions: Working the Cases April Fritz, RHIT, CTR Donna M. Gress, RHIT, CTR Jennifer Ruhl, RHIT, CCS, CTR This presentation was supported by the Cooperative
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationOverview. Collecting Cancer Data: Colon 11/5/2009. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda NAACCR WEBINAR SERIES
Collecting Cancer Data: Colon 11/5/2009 Collecting Cancer Data: Colon/Rectum/Appendix NAACCR 2009 2010 WEBINAR SERIES Agenda Overview Treatment MP/H Rules CSv2 2 Overview Colon/Rectum/Appendix 2009 2010
More informationACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA
ACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA ACHIEVING EXCELLENCE IN ABSTRACTING LYMPHOMA Recoding Audit Performed in 2009 260 cases audited 17 data items audited per case 4420 possible discrepancies
More informationNAACCR Webinar Series 1
NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Kidney 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes 3 NAACCR 2009 2010 Webinar
More informationQ: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?
Q&A Session for Collecting Cancer Data: Ovary Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report? A: We reviewed both the
More informationCoding Pitfalls 9/11/14
Coding Pitfalls 2013 2014 NAACCR Webinar Series September 11, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationColon, Rectum, and Appendix. Presentation Outline. Overview Tumor Characteristics
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More informationColon, Rectum, and Appendix
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More informationSummary Stage 2018 (SS2018)
Summary Stage 2018 (SS2018) NAACCR October Webinar October 24, 2018 General Information 2 Summary Stage 2018 1 General Summary Stage is ANATOMICALLY based Unlike AJCC, it does not use the following in
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More information2010 Update. NAACCR Webinar Series 1 4/1/2010. Agenda. Access to 2010 Information. CSv2. Collecting Cancer Data: Soft Tissue Sarcoma
NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Soft Tissue Sarcoma, Neuroendocrine Tumors (NET) and Gastrointestinal Stromal Tumors (GIST) Agenda Updates Soft Tissue Sarcoma Overview CSv2 MP/H
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationCollaborative Stage. Site-Specific Instructions - LUNG
Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each
More informationAJCC-NCRA Education Needs Assessment Results
AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners
More informationAJCC 7 th Edition Staging Disease Site Webinar Colorectum
AJCC 7 th Edition Staging Disease Site Webinar Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310
More information7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Colorectum. Overview. This webinar is sponsored by
AJCC 7 th Edition Staging Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationUsing the 7 th edition American Joint Commission on Cancer (AJCC) Cancer Staging Manual to Determine Esophageal Cancer Staging in SEER-Medicare Data
Paper PH10 Using the 7 th edition American Joint Commission on Cancer (AJCC) Cancer Staging Manual to Determine Esophageal Cancer Staging in SEER-Medicare Data Johnita L. Byrd, Emory University School
More informationPancreas Case Scenario #1
Pancreas Case Scenario #1 An 85 year old white female presented to her primary care physician with increasing abdominal pain. On 8/19 she had a CT scan of the abdomen and pelvis. This showed a 4.6 cm mass
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationOutline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.
1 How to Use the AJCC Cancer Staging Manual, 7 th ed. FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015 Steven Peace, CTR Outline 2 History, Purpose and Background Purchase and Ordering Information
More informationGastrointestinal Tract Cancer
Gastrointestinal Tract Cancer Tumors of the Stomach Gastric adenocarcinoma Incidence and Epidemiology Incidence mortality rates USA High incidence: Japan, China, Chile, Ireland risk lower socioeconomic
More informationThyroid and Adrenal Gland
Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More information2018 Implementation: SEER Summary Stage 2018
2018 Implementation: SEER Summary Stage 2018 PRESENTED BY JENNIFER RUHL OCTOBER 24, 2018 10/23/2018 1 Q&A Please submit all questions concerning the content of the webinar through the Q&A panel Submit
More informationCollaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
More informationExercise 15: CSv2 Data Item Coding Instructions ANSWERS
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report
More informationAJCC 7th Edition Handbook Errata as of 9/21/10
5 81 Larynx ICD-O-3 Topography Codes Delete C32.3 Laryngeal cartilage 5 81 Larynx ICD-O-3 Topography Codes Add an asterisk after C32.8 5 81 Larynx ICD-O-3 Topography Codes Add an asterisk after C32.9 5
More informationKidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification
Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification A1: Yes. See below. I don't think it will have a start date. Clarification
More informationUICC TNM 8 th Edition Errata
UICC TNM 8 th Edition Errata ions are in italics Page 28 Oropharynx p16 positive Pathological Stage II,T2 N2 M0 T3 N0,N1 M0 Stage II,T2 N2 M0 T3,T4 N0,N1 M0 Page 61 Oesophagus Adenocarcinoma Pathological
More informationAJCC TNM STAGING UPDATES ARE YOU READY FOR TNM?
AJCC TNM STAGING UPDATES ARE YOU READY FOR TNM? FCRA Annual Conference Boca Raton, Florida 7/26/2016 Steven Peace, CTR 1 Introduction Order AJCC Cancer Staging Manual, 7 th ed. How To Use - AJCC Cancer
More informationMCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR
MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and
More informationUpdate on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017
Update on staging colorectal carcinoma, the 8 th edition AJCC Dale C. Snover, MD November 3, 2017 General overview of staging Reason for uniform staging Requirements to use AJCC manual and/or CAP protocols
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Skin Malignancies 2/4/2010 NAACCR 2009 2010 Webinar Series Questions Please use the Q&A panel to submit your questions Send questions to All Panelist Collecting Cancer Data: Skin
More informationUICC TNM 8 th Edition Errata
UICC TNM 8 th Edition Errata ions are in italics Head and Neck Tumours Pages 20, p27, p34, p38, p41, and p49 ly pn2a Metastasis in a single ipsilateral lymph node, less than 3cm in greatest dimension with
More informationExplaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging
Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement
More informationNAACCR Webinar 2018 SeriesImplementations and Timelines
NAACCR 2015-2016 Webinar 2018 SeriesImplementations and Timelines August 8, 2017 Session 1 Q&A Please submit all questions concerning webinar content through the Q&A panel. A recording of today s session,
More informationExplaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging
Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement
More informationGastric Cancer in a Young Postpartum Female. Kings County Hospital Center SUNY Downstate Case Conference May 24, 2012
Gastric Cancer in a Young Postpartum Female Kings County Hospital Center SUNY Downstate Case Conference May 24, 2012 Case HPI: 31 yo F, G5P3, 3 weeks s/p C-section, with gastric outlet obstruction. Pt
More informationSeventh Edition Staging 2017 Colorectum. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express
More informationICD-O-3 UPDATES - PENDING
ICD-O-3 UPDATES - PENDING FCDS Annual Meeting July 26, 2013 Sunrise, Florida Steven Peace, CTR ICD-O-3 Work Group ICD-O-3 WORK GROUP Name April Fritz, CTR Lynn Ries, MS Lois Dickie, CTR Linda Mulvihill,
More informationICD-O-3 UPDATES - PENDING
ICD-O-3 UPDATES - PENDING FCDS Annual Meeting July 26, 2013 Sunrise, Florida Steven Peace, CTR ICD-O-3 Work Group ICD-O-3 WORK GROUP Name April Fritz, CTR Lynn Ries, MS Lois Dickie, CTR Linda Mulvihill,
More informationCarcinoembryonic Antigen
Other Names/Abbreviations CEA 190.26 - Carcinoembryonic Antigen Carcinoembryonic antigen (CEA) is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring
More informationStaging for Residents, Nurses, and Multidisciplinary Health Care Team
Staging for Residents, Nurses, and Multidisciplinary Health Care Team Donna M. Gress, RHIT, CTR Validating science. Improving patient care. Learning Objectives Introduce the concept and history of stage
More information2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018?
2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018? SESSION 2 10/20/17 Q&A Please submit all questions concerning webinar content through the Q&A panel. A recording of today s session, the Q&A,
More informationMajor Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging
AJCC 8 th Edition Staging Major Rule Changes Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving patient
More informationACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
More informationCS Tumor Size. GISTStomach. Collaborative Stage for TNM 7 - Revised 01/27/2010 [ Schema ]
GISTStomach Collaborative Stage for TNM 7 - Revised 01/27/2010 [ Schema ] CS Tumor Size Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is
More informationThis form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationCoding Pitfalls 9/11/14
Coding Pitfalls 2013 2014 NAACCR Webinar Series September 11, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I SUMMARY OF YEAR 2004 DATA CHANGES This document will provide a summary
More informationStaging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates
Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education
More informationInstructions for Coding Grade for 2014+
Instructions for Coding for 2014+ GRADE, DIFFERENTIATION OR CELL INDICATOR Item Length: 1 NAACCR Item #: 440 NAACCR Name:, Differentiation for solid tumors (Codes 1, 2, 3, 4, 9) and Cell Indicator for
More informationCEA (CARCINOEMBRYONIC ANTIGEN)
(CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant
More informationProtocol for the Examination of Specimens From Patients With Carcinoma of the Stomach
Protocol for the Examination of Specimens From Patients With Carcinoma of the Stomach Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual For
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationAJCC Cancer Staging 8 th Edition
AJCC Cancer Staging 8 th Edition Colon and Rectal Cancer Staging Update Webinar George J Chang, MD, MS Deputy Chair, Department of Surgical Oncology Chief, Colon and Rectal Surgery Professor of Surgical
More informationLOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.
Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004
More informationTopics: Staging and treatment for pancreatic cancer. Staging systems for pancreatic cancer: Differences between the Japanese and UICC systems
M. J Hep Kobari Bil Pancr and S. Surg Matsuno: (1998) Staging 5:121 127 system for pancreatic cancer 121 Topics: Staging and treatment for pancreatic cancer Staging systems for pancreatic cancer: Differences
More informationEVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013
EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 Head and Neck Coding and Staging Head and Neck Coding and Staging Anatomy & Primary Site Sequencing and MPH
More informationA916: rectum: adenocarcinoma
General facts of colorectal cancer The colon has cecum, ascending, transverse, descending and sigmoid colon sections. Cancer can start in any of the r sections or in the rectum. The wall of each of these
More information2018 Summary Stage PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Summary Stage PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgement Jennifer Ruhl, NCI SEER 3 Introduction 2018 SUMMARY STAGE 2018 Summary Stage 4 First update since 2001
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm
More informationTake Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
More informationSEER Summary Stage Still Here!
SEER Summary Stage Still Here! CCRA NORTHERN REGION STAGING SYMPOSIUM SEPTEMBER 20, 2017 SEER Summary Stage Timeframe: includes all information available through completion of surgery(ies) in the first
More informationSeventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Melanoma Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More informationOriginal Article. Cancer December 1,
Analysis of Stage and Clinical/Prognostic Factors for Colon and Rectal Cancer From SEER Registries: AJCC and Collaborative Stage Data Collection System Vivien W. Chen, PhD 1 ; Mei-Chin Hsieh, MSPH 1 ;
More informationQ&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014
Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q: If polycythemia ruba vera (PRV) or essential thrombocythemia (ET) is diagnosed by peripheral smear,
More informationColon and Rectum 5/1/14
Collecting Cancer Data: Colon and Rectum 2013 2014 NAACCR Webinar Series May 1, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants
More informationCODING PRIMARY SITE. Nadya Dimitrova
CODING PRIMARY SITE Nadya Dimitrova OUTLINE What is coding and why do we need it? ICD-10 and ICD-O ICD-O-3 Topography coding rules ICD-O-3 online WHAT IS CODING AND WHY DO WE NEED IT? Coding: to assign
More informationIcd 10 code for esophageal cancer stage 4
Icd 10 code for esophageal cancer stage 4 Search Risk factors for developing esophageal cancer include.. 150. 4 Malignant neoplasm of middle third of esophagus convert 150. 4 to ICD - 10 -CM;. Free ICD
More informationQ&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012
Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012 Q: Will sticky notes be transferrable from the previous electronic version of CS to the updated version? A: It is our
More informationCDC & Florida DOH Attribution
FCDS Annual Educational Conference Tampa, Florida July 19, 2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution We acknowledge the Centers for Disease Control and Prevention, for its support of the Florida
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More information2018 New Grade Coding Rules It s a Good Thing!
2018 New Grade Coding Rules It s a Good Thing! Presented by Donna M. Hansen, CTR California Cancer Registry NAACCR Webinar May 1, 2018 & May 2, 2018 1 Acknowledgement Special Thanks To: Jennifer Ruhl,
More informationA Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR
A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR Survey Questions and Answers 250 Responses 2 Question #1 A gentleman
More informationNAACCR Webinar Series
NAACCR 2009-2010 Webinar Series Collecting Cancer Data: Lip & Oral Cavity 8/5/2010 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes! NAACCR 2009/2010
More informationUterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!
Uterine October 7, 2010 NAACCR 2010-2011 Webinar Series Session 1 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes!!! 3 NAACCR 2010-2011 Webinar
More informationI.2 CNExT This section was software specific and deleted in 2008.
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION
More informationQ: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.
Q&A Breast Webinar Q: One of my investigators is interested in knowing when Oncotype DX data collection was implemented. That data is collected in SSFs 22 and 23. I remember that the SSFs for breast were
More information